Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Open in Screener

SRRK

Scholar Rock Holding Corp

Oct 22 • 04:00PM ET

29.10

Dollar change -0.86
Percentage change -2.87	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN NBIX SRPT BMRN RARE FOLD IONS BLUE CARA

| Held by: IWM XBI VTI IWO IBB SCHA VXF IWC LABU VTWO

Index	RUT	P/E	-	EPS (ttm)	-2.33	Insider Own	16.83%	Shs Outstand	75.98M	Perf Week	1.96%
Market Cap	2.63B	Forward P/E	-	EPS next Y	-2.05	Insider Trans	-9.43%	Shs Float	75.10M	Perf Month	235.64%
Income	-203.85M	PEG	-	EPS next Q	-0.57	Inst Own	84.69%	Short Float	21.99%	Perf Quarter	229.19%
Sales	0.00M	P/S	-	EPS this Y	-13.54%	Inst Trans	-0.95%	Short Ratio	9.19	Perf Half Y	96.75%
Book/sh	1.67	P/B	17.42	EPS next Y	9.40%	ROA	-79.66%	Short Interest	16.52M	Perf Year	280.89%
Cash/sh	2.11	P/C	13.79	EPS next 5Y	-	ROE	-121.29%	52W Range	6.76 - 35.38	Perf YTD	54.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.79%	ROI	-105.14%	52W High	-17.75%	Beta	0.87
Dividend TTM	-	Quick Ratio	6.04	Sales past 5Y	-5.25%	Gross Margin	-	52W Low	330.47%	ATR (14)	2.52
Dividend Ex-Date	-	Current Ratio	6.04	EPS Y/Y TTM	-2.48%	Oper. Margin	0.00%	RSI (14)	70.62	Volatility	5.54% 10.50%
Employees	150	Debt/Eq	0.51	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	37.38
Option/Short	Yes / Yes	LT Debt/Eq	0.45	EPS Q/Q	-27.65%	Payout	-	Rel Volume	0.73	Prev Close	29.96
Sales Surprise	-	EPS Surprise	-1.63%	Sales Q/Q	-	Earnings	Aug 08 BMO	Avg Volume	1.80M	Price	29.10
SMA20	41.13%	SMA50	114.06%	SMA200	123.54%	Trades		Volume	1,309,743	Change	-2.87%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-07-24	Reiterated	H.C. Wainwright	Buy	$30 → $35
Mar-28-24	Initiated	Raymond James	Strong Buy	$30
Oct-25-23	Upgrade	Jefferies	Hold → Buy	$20
Apr-03-23	Resumed	Piper Sandler	Overweight	$26
Sep-19-22	Resumed	H.C. Wainwright	Buy	$30
Jul-12-22	Initiated	Truist	Buy	$20
Mar-23-22	Initiated	H.C. Wainwright	Buy	$24
Dec-22-21	Downgrade	Jefferies	Buy → Hold	$52 → $28
Nov-19-21	Initiated	Piper Sandler	Overweight	$56
Apr-26-21	Resumed	Credit Suisse	Outperform	$65
Jan-11-21	Initiated	Credit Suisse	Outperform	$65
Jan-06-21	Initiated	JP Morgan	Overweight	$59
Mar-12-20	Initiated	Robert W. Baird	Outperform	$35

Show Previous Ratings

Oct-22-24 08:00AM	Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering (Business Wire)
Oct-21-24 09:55AM	Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross? (Zacks)
Oct-18-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-11-24 06:30PM	PBF Energy, Gold Reserve, and More Stocks See Action From Activist Investors (Barrons.com) +7.58%
Oct-09-24 05:34PM	Scholar Rock Holding Corp (SRRK) Q2 2024 Earnings Call Highlights: Advancing Key Milestones in ... (GuruFocus.com) -5.83% -5.87%
05:38AM	Loading…
05:38AM	Here's Why Everybody's Talking About Scholar Rock Right Now (Motley Fool)
Oct-08-24 11:08PM	Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire) -13.97%
08:29AM	Scholar Rocks SMA Treatment Trials Show Promising Results (TipRanks)
06:43AM	Scholar Rock stocks skyrocket after SMA drug scores at Phase III (Clinical Trials Arena)
Oct-07-24 04:13PM	Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily) +361.99%
04:09PM	Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
03:23PM	Scholar Rock Shares Quadruple On Positive Drug-Study Results (The Wall Street Journal)
11:05AM	Scholar Rock stock surges on positive spinal muscular atrophy treatment data (Investing.com)
11:05AM	Scholar Rock Stock Quadruples on Positive Trial Data (Barrons.com)
09:41AM	Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily)
07:00AM	Loading…
07:00AM	Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA) (Business Wire)
Sep-27-24 06:13AM	Scholar Rock Holding Corporation (NASDAQ:SRRK) Ranks High On The List Of Worst Falling Stocks To Buy Now (Insider Monkey)
Sep-13-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.48%
Sep-10-24 08:00AM	Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity (Business Wire) +5.89%
Sep-05-24 12:02AM	Scholar Rock Holding Corporation (SRRK): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-04-24 08:00AM	Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer (Business Wire)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 08:00AM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
Aug-16-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-15-24 04:32AM	Scholar Rocks apitegromab shows promise for non-ambulatory SMA (Clinical Trials Arena)
Aug-09-24 05:05AM	Q2 2024 Scholar Rock Holding Corp Earnings Call (Thomson Reuters StreetEvents)
Aug-08-24 07:00AM	Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress (Business Wire)
Jul-23-24 08:00AM	Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 (Business Wire)
Jul-12-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-08-24 06:42PM	Scholar Rock Holding Corporation (SRRK): The Most Shorted Stock Loved by Analysts? (Insider Monkey)
12:30PM	Loading…
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jun-24-24 07:00AM	Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal (Business Wire)
Jun-18-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-03-24 04:00PM	Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting (Business Wire)
May-28-24 08:00AM	Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting (Business Wire)
May-22-24 07:00AM	Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity (Business Wire)
May-20-24 08:00AM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
May-17-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -12.78%
May-14-24 08:00AM	Scholar Rock to Host Investor Day on May 22, 2024 (Business Wire)
May-07-24 01:53PM	SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q1 2024 (InvestorPlace)
10:19AM	Scholar Rock Shares Fall on Wider-Than-Expected Q1 Loss (MT Newswires)
08:52AM	Scholar Rock Holding Corp (SRRK) Reports Q1 2024 Financial Results: A Detailed Analysis (GuruFocus.com)
07:00AM	Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress (Business Wire)
Apr-24-24 06:33AM	3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains (InvestorPlace)
Apr-12-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.08%
Mar-20-24 05:31AM	Scholar Rock Holding Corp Reports Full Year 2023 Financial Results (GuruFocus.com) +8.58%
Mar-19-24 10:52PM	SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q4 2023 (InvestorPlace) +14.77%
07:00AM	Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress (Business Wire)
Mar-15-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.65%
08:18AM	Billionaire Paul Tudor Jones and Insiders Love These 10 Stocks (Insider Monkey)
Feb-28-24 08:00AM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
Feb-16-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.42%
Feb-15-24 08:00AM	Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer (Business Wire)
Feb-06-24 08:00AM	Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management (Business Wire)
Jan-25-24 08:00AM	Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia (Business Wire)
Jan-23-24 08:00AM	Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity (Business Wire)
Jan-22-24 07:00AM	Obesity Drugs Lead to Muscle LossPharma Companies Want to Fix That (The Wall Street Journal)
Jan-18-24 05:01PM	Insider Edward Myles Sells 6,634 Shares of Scholar Rock Holding Corp (SRRK) (GuruFocus.com) -5.10%
Jan-12-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-04-24 08:00AM	Scholar Rock Provides Corporate Update and Highlights Priorities for 2024 (Business Wire)
Jan-02-24 01:57PM	3 Biotech Stocks at the Forefront of the Quest for Eternal Youth (InvestorPlace) -6.91%
Dec-30-23 07:01PM	Insider Edward Myles Sells 12,459 Shares of Scholar Rock Holding Corp (SRRK) (GuruFocus.com)
Dec-19-23 08:00AM	Scholar Rock to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +5.29%
Dec-15-23 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.43%
Dec-10-23 09:05AM	Insider Sell: COO & CFO Edward Myles Sells 24,914 Shares of Scholar Rock Holding Corp (SRRK) (GuruFocus.com)
Nov-17-23 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-12-23 12:32PM	Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 08:14AM	Scholar Rock Holding Corp (SRRK) Reports Q3 2023 Financial Results (GuruFocus.com)
07:15AM	Scholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business Progress (Business Wire)
Nov-06-23 09:55AM	Wall Street Analysts See a 99.11% Upside in Scholar Rock Holding Corporation (SRRK): Can the Stock Really Move This High? (Zacks)
Nov-03-23 11:52PM	Insider Sell: Edward Myles Sells 35,007 Shares of Scholar Rock Holding Corp (SRRK) (GuruFocus.com)
04:00PM	Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability (Business Wire)
Nov-02-23 08:00AM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
Oct-31-23 08:50AM	Here's Why 'Trend' Investors Would Love Betting on Scholar Rock Holding Corporation (SRRK) (Zacks)
Oct-24-23 12:00PM	All You Need to Know About Scholar Rock Holding Corporation (SRRK) Rating Upgrade to Strong Buy (Zacks)
Oct-23-23 08:00AM	Scholar Rock to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023 (Business Wire)
Oct-19-23 09:55AM	Wall Street Analysts Think Scholar Rock Holding Corporation (SRRK) Could Surge 203.99%: Read This Before Placing a Bet (Zacks)
08:00AM	Scholar Rock to Present Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 38th Annual Meeting (Business Wire)
Oct-18-23 08:30AM	Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More (Zacks) -13.56%
Oct-16-23 04:15PM	Scholar Rock Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares (Business Wire) +5.36% +5.33%
Oct-13-23 12:45PM	Scholar Rock (SRRK) Up on Pipeline Advancement, Stock Offering (Zacks)
Oct-12-23 04:17PM	Why Scholar Rock Holding Stock Soared Today (Motley Fool) +17.66%
Oct-11-23 08:57PM	Scholar Rock Announces Pricing of Upsized Public Offering of Common Stock (Business Wire)
05:05PM	Scholar Rock Announces Proposed Public Offering of Common Stock (Business Wire)
04:44PM	Scholar Rock to Advance Antimyostatin Program to Develop Novel Therapies for Cardiometabolic Disorders (Business Wire)
Sep-19-23 08:00AM	Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial (Business Wire) +10.74%
Sep-15-23 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-07-23 09:55AM	Wall Street Analysts Believe Scholar Rock Holding Corporation (SRRK) Could Rally 264.53%: Here's is How to Trade (Zacks)
Aug-18-23 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.93%
Aug-09-23 04:15PM	Scholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business Progress (Business Wire) +11.33%
Aug-02-23 10:41AM	Too Cheap to Ignore: J.P. Morgan Says These 2 Stocks Under $10 Could Double Your Money (TipRanks) +6.86%
Jul-13-23 08:00AM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-30-23 11:00AM	New 36-Month Apitegromab Extension Data Reinforce Long-Term Substantial and Sustained Improvement of Motor Function in Phase 2 TOPAZ Trial Patients with Nonambulatory Spinal Muscular Atrophy (Business Wire) +10.07%
Jun-15-23 08:00AM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-01-23 04:05PM	Scholar Rock to Present at the Jefferies Healthcare Conference (Business Wire) +6.45%
May-10-23 08:00AM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-09-23 07:30AM	Scholar Rock Reports First Quarter 2023 Financial Results and Highlights Business Progress (Business Wire) +5.98%
May-08-23 08:00AM	Scholar Rock to Present New Data Evaluating Apitegromab at 36 Months from the Phase 2 TOPAZ trial at the 2023 Annual Cure SMA Conference (Business Wire)
Apr-17-23 12:57PM	Scholar Rock Holding Corporation's (NASDAQ:SRRK) Business Is Trailing The Industry But Its Shares Aren't (Simply Wall St.)
Apr-12-23 08:00AM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Myles Edward H	COO & CFO	Oct 08 '24	Option Exercise	10.00	37,187	371,870	198,275	Oct 10 06:00 PM
Myles Edward H	COO & CFO	Oct 08 '24	Sale	34.90	37,187	1,297,659	161,088	Oct 10 06:00 PM
Myles Edward H	COO & CFO	Oct 07 '24	Sale	26.56	206,240	5,477,546	161,088	Oct 07 09:52 PM
Sacco Tracey	CHIEF COMMERCIAL OFFICER	Oct 07 '24	Option Exercise	10.00	30,000	300,000	79,285	Oct 07 09:03 PM
Sacco Tracey	CHIEF COMMERCIAL OFFICER	Oct 07 '24	Sale	25.62	30,000	768,677	49,285	Oct 07 09:03 PM
AKKARAJU SRINIVAS	Director	Oct 07 '24	Sale	29.25	1,175,713	34,385,672	5,612,896	Oct 07 08:55 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Oct 07 '24	Option Exercise	8.59	109,375	939,531	182,230	Oct 07 08:51 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Oct 07 '24	Sale	27.21	109,375	2,976,468	72,855	Oct 07 08:51 PM
AKKARAJU SRINIVAS	Director	Oct 07 '24	Proposed Sale	29.25	1,175,713	34,385,725		Oct 07 08:43 PM
Tracey Sacco	Officer	Oct 07 '24	Proposed Sale	25.62	30,000	768,693		Oct 07 04:20 PM
Jing Marantz	Officer	Oct 07 '24	Proposed Sale	32.50	120,000	3,900,000		Oct 07 04:18 PM
Edward Myles	Officer	Oct 07 '24	Proposed Sale	32.50	243,427	7,911,378		Oct 07 04:16 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Sep 16 '24	Sale	8.58	1,936	16,611	142,768	Sep 19 08:15 AM
Parlavecchio Caryn	CHRO	Aug 16 '24	Sale	9.33	1,451	13,538	151,988	Aug 19 05:00 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jun 17 '24	Sale	8.98	2,315	20,800	144,704	Jun 18 05:56 PM
Parlavecchio Caryn	CHRO	Jun 17 '24	Sale	8.98	4,305	38,680	153,439	Jun 18 05:55 PM
Myles Edward H	COO & CFO	Jun 17 '24	Sale	8.98	9,458	84,978	201,518	Jun 18 05:54 PM
Ho Junlin	GENERAL COUNSEL	Jun 17 '24	Sale	8.98	4,695	42,183	204,076	Jun 18 05:53 PM
Myles Edward H	COO & CFO	Feb 16 '24	Sale	15.74	4,744	74,686	210,976	Feb 21 06:13 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 16 '24	Sale	15.74	2,512	39,547	147,019	Feb 20 04:58 PM
Parlavecchio Caryn	CHRO	Feb 16 '24	Sale	15.74	3,751	59,053	157,744	Feb 20 04:52 PM
Ho Junlin	GENERAL COUNSEL	Feb 16 '24	Sale	15.74	3,489	54,928	208,771	Feb 20 04:48 PM
Backstrom Jay T.	CHIEF EXECUTIVE OFFICER	Feb 16 '24	Sale	15.74	11,614	182,842	352,671	Feb 20 04:46 PM
Qatanani Mo	SVP AND HEAD OF RESEARCH	Jan 16 '24	Sale	15.93	2,002	31,889	78,816	Jan 18 04:11 PM
Parlavecchio Caryn	CHRO	Jan 16 '24	Sale	15.93	2,849	45,381	114,350	Jan 18 04:08 PM
Myles Edward H	COO & CFO	Jan 16 '24	Sale	15.93	6,634	105,670	162,150	Jan 18 04:07 PM
Ho Junlin	GENERAL COUNSEL	Jan 16 '24	Sale	15.93	4,186	66,677	154,405	Jan 18 04:05 PM
Myles Edward H	COO & CFO	Dec 29 '23	Option Exercise	4.86	12,459	60,551	181,243	Dec 29 07:13 PM
Myles Edward H	COO & CFO	Dec 29 '23	Sale	18.83	12,459	234,633	168,784	Dec 29 07:13 PM
Qatanani Mo	SVP AND HEAD OF RESEARCH	Dec 14 '23	Option Exercise	10.00	8,437	84,370	105,480	Dec 15 04:13 PM
Qatanani Mo	SVP AND HEAD OF RESEARCH	Dec 14 '23	Sale	18.18	24,662	448,444	80,818	Dec 15 04:13 PM
Myles Edward H	COO & CFO	Dec 07 '23	Option Exercise	4.86	24,914	121,082	193,698	Dec 08 04:12 PM
Myles Edward H	COO & CFO	Dec 07 '23	Sale	17.53	24,914	436,820	168,784	Dec 08 04:12 PM
Myles Edward H	COO & CFO	Nov 02 '23	Sale	12.51	35,007	438,039	168,784	Nov 03 06:11 PM

Open in Screener

ALMS

Alumis Inc.

Oct 22 • 04:00PM ET

12.98

Dollar change +0.40
Percentage change 3.18	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD REGN VRTX BIIB MRNA INCY BMY ABBV PFE

| Held by: VTI IWM VXF IWO SCHA IWN VTWO IWC SCHB RSSL

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	50.18%	Shs Outstand	44.66M	Perf Week	15.89%
Market Cap	612.92M	Forward P/E	-	EPS next Y	-	Insider Trans	46.31%	Shs Float	23.53M	Perf Month	9.44%
Income	-	PEG	-	EPS next Q	-1.51	Inst Own	34.19%	Short Float	9.10%	Perf Quarter	1.29%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	12.77	Perf Half Y	-
Book/sh	-8.06	P/B	-	EPS next Y	-	ROA	-	Short Interest	2.14M	Perf Year	-
Cash/sh	4.44	P/C	2.92	EPS next 5Y	-	ROE	-	52W Range	9.54 - 13.53	Perf YTD	-2.41%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-4.07%	Beta	-
Dividend TTM	-	Quick Ratio	6.73	Sales past 5Y	0.00%	Gross Margin	-	52W Low	36.06%	ATR (14)	0.77
Dividend Ex-Date	-	Current Ratio	6.73	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	68.72	Volatility	8.07% 7.10%
Employees	-	Debt/Eq	0.16	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	31.75
Option/Short	No / Yes	LT Debt/Eq	0.15	EPS Q/Q	-	Payout	-	Rel Volume	0.51	Prev Close	12.58
Sales Surprise	-	EPS Surprise	14.04%	Sales Q/Q	-	Earnings	Aug 13 AMC	Avg Volume	167.70K	Price	12.98
SMA20	18.33%	SMA50	11.34%	SMA200	9.11%	Trades		Volume	85,167	Change	3.18%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-17-24	Initiated	H.C. Wainwright	Buy	$30
Jul-23-24	Initiated	Morgan Stanley	Overweight	$36
Jul-23-24	Initiated	Leerink Partners	Outperform	$29
Jul-23-24	Initiated	Guggenheim	Buy	$32
Jul-23-24	Initiated	Cantor Fitzgerald	Overweight

Sep-27-24 09:00AM	Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study (GlobeNewswire) -6.77%
Sep-03-24 04:29PM	Alumis to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-13-24 04:05PM	Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements (GlobeNewswire)
Jul-29-24 08:00AM	Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis (GlobeNewswire)
Jun-27-24 11:57PM	Alumis Announces Pricing of Initial Public Offering (GlobeNewswire)

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Foresite Labs, LLC	10% Owner	Jul 01 '24	Buy	16.00	2,500,000	40,000,000	5,584,889	Jul 03 09:31 PM
Foresite Capital Management V,	10% Owner	Jul 01 '24	Buy	16.00	2,500,000	40,000,000	5,584,889	Jul 03 09:30 PM
Tananbaum James B.	Director	Jul 01 '24	Buy	16.00	2,500,000	40,000,000	5,584,889	Jul 03 09:30 PM

Open in Screener

SYRS

Syros Pharmaceuticals Inc.

Oct 22 • 04:00PM ET

2.47

Dollar change +0.23
Percentage change 10.27	%

Healthcare • Biotechnology • USA • NASD

SYRS Syros Pharmaceuticals Inc. daily Stock Chart

Peers: VRTX BMRN BLUE RGEN IONS CRSP NTLA EDIT FATE SGMO

| Held by: VTI VXF IWC AVSC

Index	-	P/E	-	EPS (ttm)	-4.30	Insider Own	26.31%	Shs Outstand	26.45M	Perf Week	24.12%
Market Cap	66.22M	Forward P/E	-	EPS next Y	-2.71	Insider Trans	2.40%	Shs Float	19.76M	Perf Month	31.38%
Income	-131.56M	PEG	-	EPS next Q	-0.68	Inst Own	56.13%	Short Float	5.06%	Perf Quarter	-57.41%
Sales	4.15M	P/S	15.96	EPS this Y	64.31%	Inst Trans	-5.85%	Short Ratio	2.71	Perf Half Y	-51.95%
Book/sh	-0.24	P/B	-	EPS next Y	-30.50%	ROA	-91.46%	Short Interest	1.00M	Perf Year	11.76%
Cash/sh	2.95	P/C	0.84	EPS next 5Y	-	ROE	-393.39%	52W Range	1.43 - 8.17	Perf YTD	-68.29%
Dividend Est.	-	P/FCF	-	EPS past 5Y	21.16%	ROI	-253.91%	52W High	-69.77%	Beta	1.62
Dividend TTM	-	Quick Ratio	3.46	Sales past 5Y	128.79%	Gross Margin	62.39%	52W Low	72.73%	ATR (14)	0.18
Dividend Ex-Date	-	Current Ratio	3.46	EPS Y/Y TTM	22.30%	Oper. Margin	-2835.68%	RSI (14)	68.29	Volatility	12.52% 7.25%
Employees	68	Debt/Eq	-	Sales Y/Y TTM	-53.52%	Profit Margin	-3171.70%	Recom	1.00	Target Price	8.75
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	54.27%	Payout	-	Rel Volume	3.61	Prev Close	2.24
Sales Surprise	-100.00%	EPS Surprise	23.12%	Sales Q/Q	-100.00%	Earnings	Jul 31 BMO	Avg Volume	369.58K	Price	2.47
SMA20	23.41%	SMA50	35.38%	SMA200	-49.91%	Trades		Volume	1,267,340	Change	10.27%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-20	Upgrade	H.C. Wainwright	Neutral → Buy	$11 → $15
Sep-22-20	Initiated	Alliance Global Partners	Buy	$18
Jan-17-20	Downgrade	Wedbush	Outperform → Neutral
Mar-08-19	Resumed	JMP Securities	Mkt Outperform	$18
Feb-14-19	Resumed	Oppenheimer	Outperform	$13
Nov-05-18	Upgrade	ROTH Capital	Neutral → Buy
Mar-13-18	Reiterated	Wedbush	Outperform	$11 → $13
Oct-31-17	Resumed	Piper Jaffray	Overweight	$30
Oct-23-17	Initiated	ROTH Capital	Neutral	$15
Aug-10-17	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform

Oct-09-24 03:33PM	Syros Pharmaceuticals Inc (SYRS) Q2 2024 Earnings Call Highlights: Strategic Focus on ... (GuruFocus.com)
Sep-12-24 07:00PM	Insider Buying: CFO Jason Haas Acquires 100,000 Shares of Syros Pharmaceuticals Inc (SYRS) (GuruFocus.com) +24.20%
07:00PM	Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS) (GuruFocus.com)
Aug-27-24 07:00AM	Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences (Business Wire) -5.99%
Aug-14-24 10:19AM	Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination (Zacks) -15.89%
09:35AM	Loading…
09:35AM	Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-13-24 09:41AM	Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome (Benzinga) -61.68%
09:13AM	Syros stock craters after Phase II AML trial termination due to inefficacy (Pharmaceutical Technology)
Aug-12-24 04:15PM	Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial (Business Wire)
Aug-05-24 09:55AM	Does Syros Pharmaceuticals (SYRS) Have the Potential to Rally 251.92% as Wall Street Analysts Expect? (Zacks)
Jul-31-24 07:30AM	Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update (Business Wire)
Jul-24-24 07:00AM	Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024 (Business Wire)
Jul-17-24 11:24AM	Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why (Zacks)
08:00AM	Alltrna Announces Updates to Its Board of Directors (PR Newswire)
Jun-13-24 07:00AM	Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression (Business Wire) +7.41%
03:03AM	Loading…
May-15-24 03:03AM	Syros Pharmaceuticals Inc (SYRS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
01:14AM	Q1 2024 Syros Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-14-24 10:52AM	SYRS Stock Earnings: Syros Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace) +7.31%
07:30AM	Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update (Business Wire)
May-07-24 09:00AM	Syros to Participate in Upcoming Investor Conferences (Business Wire)
07:00AM	Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024 (Business Wire)
May-01-24 10:01AM	Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-10-24 09:49AM	Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML (Zacks)
08:30AM	Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock? (Zacks)
Apr-09-24 07:00AM	Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression (Business Wire) +22.22%
Apr-02-24 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.04% +7.44%
Mar-28-24 10:06AM	Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.39%
Mar-27-24 11:53AM	SYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -6.56%
07:30AM	Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update (Business Wire)
Mar-25-24 07:00AM	Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial (Business Wire)
07:00AM	Loading…
Mar-20-24 07:00AM	Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024 (Business Wire)
Feb-27-24 07:00AM	Syros to Participate in TD Cowen 44th Annual Health Care Conference (Business Wire)
Jan-31-24 04:00PM	3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential (InvestorPlace)
Jan-19-24 10:43AM	Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why (Zacks)
Jan-18-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Syros Pharmaceuticals, Inc. (SYRS) is a Great Choice (Zacks) -6.09%
Jan-17-24 08:50AM	Syros Pharmaceuticals, Inc. (SYRS) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jan-16-24 12:00PM	What Makes Syros Pharmaceuticals, Inc. (SYRS) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Predict a 199.31% Upside in Syros Pharmaceuticals, Inc. (SYRS): Here's What You Should Know (Zacks)
Jan-11-24 08:48AM	Why Syros Pharmaceuticals (SYRS) Stock Might be a Great Pick (Zacks)
Jan-08-24 07:00AM	Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene (Business Wire)
Jan-03-24 11:03PM	Steven Cohen's Point72 Asset Management Acquires New Stake in Syros Pharmaceuticals (GuruFocus.com) -9.95%
Dec-19-23 07:27AM	Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants (Business Wire) +30.93%
Dec-07-23 09:44AM	Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene (Zacks) +15.92%
Dec-06-23 07:00AM	Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine (Business Wire) +42.55%
Dec-03-23 04:17PM	Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential (InvestorPlace)
Nov-21-23 07:30AM	Syros to Participate in Upcoming Investor Conferences (Business Wire)
Nov-15-23 01:08PM	Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2023 Earnings Call Transcript (Insider Monkey) +11.76%
Nov-14-23 07:30AM	Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update (Business Wire)
Nov-07-23 07:30AM	Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023 (Business Wire) +5.36%
Oct-02-23 08:45AM	Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company (Business Wire) -18.73%
Sep-07-23 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-08-23 09:49PM	Q2 2023 Syros Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
09:05AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update (Business Wire)
Aug-04-23 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.93%
Aug-01-23 07:30AM	Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 (Business Wire)
Jul-27-23 06:29AM	The Petri Dish: Pfizer ends Syros collab; Editas hires 37-year Biogen vet (American City Business Journals)
Jul-21-23 05:40PM	Pfizer to end license deal with Syros for blood disorder therapies (Reuters)
Jul-05-23 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-22-23 08:14PM	Strength Seen in IGM Biosciences, Inc. (IGMS): Can Its 7.6% Jump Turn into More Strength? (Zacks)
Jun-13-23 08:00AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
Jun-08-23 07:30AM	Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference (Business Wire)
Jun-01-23 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-25-23 05:05PM	Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting (Business Wire) -5.06%
08:44AM	One Syros Pharmaceuticals Insider Raised Stake By 212% In Previous Year \ (Simply Wall St.)
May-13-23 10:15AM	Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-10-23 10:08PM	Q1 2023 Syros Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +10.29%
08:45AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update (Business Wire)
May-09-23 07:00AM	Syros to Present at JMP Securities 2023 Life Sciences Conference (Business Wire)
May-07-23 08:40PM	ImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar? (Zacks)
May-03-23 07:30AM	Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023 (Business Wire)
May-02-23 07:00AM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.95%
Mar-06-23 09:48AM	Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-04-23 07:08AM	Syros Pharmaceuticals Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Mar-02-23 10:02PM	Q4 2022 Syros Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
09:35AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update (Business Wire)
Feb-28-23 07:30AM	Syros to Participate in Upcoming Investor Conferences in March (Business Wire)
Feb-23-23 07:30AM	Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023 (Business Wire)
Feb-09-23 04:05PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.61%
Feb-01-23 09:43AM	Strength Seen in Syros Pharmaceuticals, Inc. (SYRS): Can Its 5.4% Jump Turn into More Strength? (Zacks)
Jan-26-23 07:00AM	Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome (Business Wire)
Jan-09-23 07:00AM	Syros Announces Clinical Updates and 2023 Strategic Priorities (Business Wire)
Dec-23-22 04:05PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-16-22 06:47AM	One Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) insider upped their stake by 212% in the previous year (Simply Wall St.) -7.73%
Dec-12-22 07:30AM	Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS (Business Wire) +5.04%
Dec-10-22 10:00AM	Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial (Business Wire)
Dec-05-22 07:00AM	Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10 (Business Wire)
Nov-22-22 07:30AM	Syros to Participate at Piper Sandler 34th Annual Healthcare Conference (Business Wire)
Nov-14-22 08:45AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -8.04%
07:30AM	Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update (Business Wire)
Nov-07-22 07:30AM	Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022 (Business Wire)
Nov-04-22 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-03-22 09:01AM	Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting (Business Wire)
Oct-05-22 04:01PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-23-22 12:00PM	Syros Pharmaceuticals, Inc. (SYRS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) -10.88%
Sep-16-22 04:05PM	Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement (Business Wire) -17.27%
Sep-15-22 04:13PM	Syros and Tyme Technologies Announce Stockholder Approval of Merger (GlobeNewswire)
Sep-14-22 01:26PM	Syros (SYRS) Up on FDA's Orphan Tag for Pancreatic Cancer Drug (Zacks) -7.56%

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chee Conley	President & CEO	Sep 11 '24	Buy	1.71	50,000	85,420	122,504	Sep 12 05:00 PM
Haas Jason	Chief Financial Officer	Sep 12 '24	Buy	1.68	45,344	76,006	124,552	Sep 12 05:00 PM
Chee Conley	President & CEO	Sep 10 '24	Buy	1.51	50,000	75,260	72,504	Sep 12 05:00 PM
Haas Jason	Chief Financial Officer	Sep 10 '24	Buy	1.55	35,363	54,788	59,915	Sep 12 05:00 PM
Haas Jason	Chief Financial Officer	Sep 11 '24	Buy	1.58	19,293	30,446	79,208	Sep 12 05:00 PM
Young Richard A	Director	Jun 28 '24	Sale	5.12	34,837	178,365	8,000	Jul 02 04:15 PM
Roth David	Chief Medical Officer	Apr 03 '24	Sale	4.95	10,451	51,732	0	Apr 05 04:30 PM
Roth David	Chief Medical Officer	Apr 02 '24	Sale	4.98	150	747	10,451	Apr 02 04:58 PM
AKKARAJU SRINIVAS	Director	Dec 21 '23	Buy	4.42	904,977	3,999,998	1,786,427	Dec 26 05:24 PM
Roth David	Chief Medical Officer	Dec 12 '23	Sale	4.95	6,287	31,121	0	Dec 14 04:24 PM
Roth David	Chief Medical Officer	Dec 06 '23	Sale	3.95	6,287	24,834	6,287	Dec 08 04:23 PM

Open in Screener

MLYS

Mineralys Therapeutics Inc

Oct 22 • 04:00PM ET

13.95

Dollar change +0.12
Percentage change 0.87	%

Healthcare • Biotechnology • USA • NASD

MLYS Mineralys Therapeutics Inc daily Stock Chart

Peers: FENC AKBA EOLS ARDX ESPR PDSB KNSA ACXP CRVS ATHE

| Held by: IWM VTI VXF IWN IBB HRTS VTWO SCHA IWC IWO

Index	RUT	P/E	-	EPS (ttm)	-2.69	Insider Own	54.80%	Shs Outstand	41.13M	Perf Week	1.82%
Market Cap	693.73M	Forward P/E	-	EPS next Y	-3.36	Insider Trans	-2.93%	Shs Float	22.48M	Perf Month	21.83%
Income	-119.67M	PEG	-	EPS next Q	-0.86	Inst Own	45.83%	Short Float	7.06%	Perf Quarter	1.45%
Sales	0.00M	P/S	-	EPS this Y	-65.66%	Inst Trans	7.55%	Short Ratio	9.37	Perf Half Y	22.05%
Book/sh	5.84	P/B	2.39	EPS next Y	-1.98%	ROA	-39.26%	Short Interest	1.59M	Perf Year	66.87%
Cash/sh	6.26	P/C	2.23	EPS next 5Y	-	ROE	-41.62%	52W Range	5.85 - 16.91	Perf YTD	62.21%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-41.25%	52W High	-17.48%	Beta	1.91
Dividend TTM	-	Quick Ratio	11.20	Sales past 5Y	0.00%	Gross Margin	-	52W Low	138.46%	ATR (14)	0.55
Dividend Ex-Date	-	Current Ratio	11.20	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	62.08	Volatility	3.91% 4.22%
Employees	28	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	32.50
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-179.61%	Payout	-	Rel Volume	0.21	Prev Close	13.83
Sales Surprise	-	EPS Surprise	-18.57%	Sales Q/Q	-	Earnings	Aug 13 AMC	Avg Volume	169.18K	Price	13.95
SMA20	5.29%	SMA50	14.34%	SMA200	11.42%	Trades		Volume	36,374	Change	0.87%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-24	Initiated	H.C. Wainwright	Buy	$30
Apr-02-24	Initiated	Goldman	Buy	$30
Mar-07-23	Initiated	Wells Fargo	Overweight	$27
Mar-07-23	Initiated	Stifel	Buy	$45
Mar-07-23	Initiated	Guggenheim	Buy	$32
Mar-07-23	Initiated	Evercore ISI	Outperform
Mar-07-23	Initiated	Credit Suisse	Outperform	$40
Mar-07-23	Initiated	BofA Securities	Buy	$39

Oct-22-24 08:00AM	Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 (GlobeNewswire)
Sep-25-24 08:00AM	Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension (GlobeNewswire)
Aug-28-24 08:00AM	Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-13-24 04:05PM	Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -22.82%
Aug-05-24 04:05PM	Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024 (GlobeNewswire) -5.66%
07:01PM	Loading…
Jul-12-24 07:01PM	Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,746 Shares (GuruFocus.com) +6.71%
07:01PM	Insider Sale at Mineralys Therapeutics Inc (MLYS): CFO and Secretary Adam Levy Sells Shares (GuruFocus.com)
Jun-21-24 03:11AM	Insider Sale: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS) (GuruFocus.com)
Jun-15-24 02:53AM	Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 72,797 Shares (GuruFocus.com)
Jun-14-24 08:00AM	Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors (GlobeNewswire)
02:43AM	Insider Sale: CFO and Secretary Adam Levy Sells 96,815 Shares of Mineralys Therapeutics Inc (MLYS) (GuruFocus.com)
Jun-03-24 08:00AM	Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-13-24 11:45AM	Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 11:56AM	MLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:00AM	Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Loading…
May-06-24 08:00AM	Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference (GlobeNewswire) +6.18%
May-02-24 08:00AM	Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024 (GlobeNewswire)
Apr-05-24 12:16AM	Goldman Sachs Predicts Over 120% Rally for These 2 Strong Buy Stocks (TipRanks)
Mar-22-24 10:51AM	Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-21-24 11:53AM	MLYS Stock Earnings: Mineralys Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
09:11AM	Mineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ... (GuruFocus.com)
07:00AM	Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-13-24 04:05PM	Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024 (GlobeNewswire)
Feb-08-24 08:00AM	Mineralys Therapeutics Announces $120 Million Private Placement Financing (GlobeNewswire) +12.51%
Jan-29-24 04:05PM	Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference (GlobeNewswire) +6.21%
Jan-17-24 12:00PM	Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jan-04-24 04:05PM	Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer (GlobeNewswire)
Dec-21-23 04:05PM	Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension (GlobeNewswire) +8.30%
Nov-12-23 09:22AM	Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-11-23 11:30AM	Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 (GlobeNewswire)
04:05PM	Loading…
Nov-09-23 04:05PM	Mineralys Therapeutics to Participate in Three Upcoming Conferences (GlobeNewswire) -9.31% -12.84%
Nov-07-23 05:12PM	Mineralys Therapeutics Inc (MLYS) Reports Q3 2023 Financials; R&D Expenses Rise Amid ... (GuruFocus.com) +8.02% -6.74%
04:05PM	Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-23 10:00AM	Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting (GlobeNewswire)
Oct-31-23 04:05PM	Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023 (GlobeNewswire)
Oct-13-23 04:10PM	Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023 (GlobeNewswire) +5.59% +5.19%
Sep-19-23 04:00PM	Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy (GlobeNewswire)
Sep-14-23 04:05PM	Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas (GlobeNewswire)
Sep-11-23 04:05PM	Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023 (GlobeNewswire)
Sep-10-23 07:47AM	Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension (GlobeNewswire)
07:45AM	Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions (GlobeNewswire)
Sep-09-23 05:00AM	CEO Jon Congleton Buys 2,250 Shares of Mineralys Therapeutics Inc (MLYS) (GuruFocus.com)
Sep-05-23 04:05PM	Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions (GlobeNewswire) -5.57%
09:55AM	Wall Street Analysts See a 199.3% Upside in Mineralys Therapeutics, Inc. (MLYS): Can the Stock Really Move This High? (Zacks)
Aug-29-23 04:05PM	Mineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023 (GlobeNewswire)
Aug-22-23 05:45PM	Mineralys Therapeutics, Inc. (MLYS) Loses -19.64% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +8.84%
Aug-07-23 04:05PM	Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -6.02% +6.96%
Jul-31-23 04:05PM	Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023 (GlobeNewswire)
Jul-17-23 04:01PM	Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD) (GlobeNewswire)
Jun-09-23 08:04AM	10 Struggling IPOs To Buy For The Long-Term (Insider Monkey)
May-31-23 08:00AM	Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-15-23 04:01PM	Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-10-23 08:39AM	We Think Mineralys Therapeutics (NASDAQ:MLYS) Can Afford To Drive Business Growth (Simply Wall St.)
May-02-23 08:00AM	Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension (GlobeNewswire)
May-01-23 08:00AM	Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023 (GlobeNewswire)
Apr-27-23 04:47PM	Mineralys Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference on Wednesday, May 10, 2023 (GlobeNewswire)
Mar-15-23 04:01PM	Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -5.93%
Mar-04-23 04:30PM	Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC (GlobeNewswire)
Mar-01-23 04:05PM	Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023 (GlobeNewswire)
Feb-20-23 08:00AM	Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023 (GlobeNewswire)
Feb-17-23 12:08PM	Lab Notes: AnPac dips into real estate with diversification strategy; Mineralys closes $220.8M IPO (American City Business Journals)
Feb-14-23 04:01PM	Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Feb-10-23 05:16PM	Mineralys, Enlight Trading Debuts Add to Big Week for US IPOs (Bloomberg)

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Levy Adam Scott	CFO and Secretary	Oct 11 '24	Sale	13.57	10,757	146,004	236,854	Oct 15 04:22 PM
Rodman David Malcom	Chief Medical Officer	Oct 14 '24	Option Exercise	1.08	5,352	5,780	135,974	Oct 15 04:22 PM
Rodman David Malcom	Chief Medical Officer	Oct 11 '24	Option Exercise	0.54	5,017	2,709	130,622	Oct 15 04:22 PM
Congleton Jon	Chief Executive Officer	Oct 11 '24	Sale	13.52	15,271	206,433	895,941	Oct 15 04:21 PM
Congleton Jon	Officer	Oct 11 '24	Proposed Sale	13.52	15,271	206,434		Oct 11 04:54 PM
Levy Adam Scott	Officer	Oct 11 '24	Proposed Sale	13.57	10,757	146,004		Oct 11 04:48 PM
Rodman David Malcom	Chief Medical Officer	Sep 12 '24	Option Exercise	1.08	6,349	6,857	125,605	Sep 12 04:32 PM
Rodman David Malcom	Chief Medical Officer	Sep 11 '24	Option Exercise	0.54	5,018	2,710	119,256	Sep 12 04:32 PM
Rodman David Malcom	Chief Medical Officer	Aug 12 '24	Option Exercise	0.84	11,365	9,565	114,238	Aug 13 04:20 PM
Slingsby Brian Taylor	Director	Jul 24 '24	Sale	13.05	550,000	7,177,500	8,644,579	Jul 26 09:45 PM
Rodman David Malcom	Chief Medical Officer	Jul 16 '24	Option Exercise	1.08	525	567	103,398	Jul 18 06:34 PM
Rodman David Malcom	Chief Medical Officer	Jul 16 '24	Sale	15.00	525	7,876	102,873	Jul 18 06:34 PM
Rodman David Malcom	Chief Medical Officer	Jul 12 '24	Option Exercise	1.08	6,349	6,857	102,873	Jul 12 04:39 PM
Rodman David Malcom	Chief Medical Officer	Jul 11 '24	Option Exercise	0.54	5,017	2,709	96,524	Jul 12 04:39 PM
Levy Adam Scott	CFO and Secretary	Jul 11 '24	Sale	13.14	10,757	141,394	247,611	Jul 12 04:37 PM
Congleton Jon	Chief Executive Officer	Jul 11 '24	Sale	13.34	15,746	210,075	911,212	Jul 12 04:36 PM
Congleton Jon	Chief Executive Officer	Jun 17 '24	Sale	12.25	17,766	217,712	958,505	Jun 20 05:44 PM
Congleton Jon	Chief Executive Officer	Jun 18 '24	Sale	11.99	16,607	199,073	941,898	Jun 20 05:44 PM
Congleton Jon	Chief Executive Officer	Jun 20 '24	Sale	11.73	14,940	175,237	926,958	Jun 20 05:44 PM
Congleton Jon	Chief Executive Officer	Jun 13 '24	Sale	12.74	39,961	509,027	992,500	Jun 14 06:15 PM
Congleton Jon	Chief Executive Officer	Jun 12 '24	Sale	12.77	16,607	212,013	1,032,461	Jun 14 06:15 PM
Congleton Jon	Chief Executive Officer	Jun 14 '24	Sale	12.52	16,229	203,163	976,271	Jun 14 06:15 PM
Levy Adam Scott	CFO and Secretary	Jun 11 '24	Sale	12.94	96,815	1,252,718	255,462	Jun 13 05:33 PM
Rodman David Malcom	Chief Medical Officer	Jun 12 '24	Option Exercise	1.08	6,349	6,857	89,729	Jun 13 05:32 PM
Rodman David Malcom	Chief Medical Officer	Jun 11 '24	Option Exercise	0.54	5,017	2,709	83,380	Jun 13 05:32 PM
Rodman David Malcom	Chief Medical Officer	May 13 '24	Option Exercise	0.84	11,366	9,566	78,363	May 15 04:43 PM
Rodman David Malcom	Chief Medical Officer	May 09 '24	Option Exercise	1.08	100	108	67,097	May 10 04:17 PM
Rodman David Malcom	Chief Medical Officer	May 09 '24	Sale	15.00	100	1,500	66,997	May 10 04:17 PM
Rodman David Malcom	Chief Medical Officer	Apr 12 '24	Option Exercise	1.08	6,349	6,857	66,997	Apr 15 04:24 PM
Rodman David Malcom	Chief Medical Officer	Apr 11 '24	Option Exercise	0.54	5,017	2,709	60,648	Apr 15 04:24 PM
Rodman David Malcom	Chief Medical Officer	Mar 12 '24	Option Exercise	1.08	6,348	6,856	55,631	Mar 13 05:35 PM
Rodman David Malcom	Chief Medical Officer	Mar 11 '24	Option Exercise	0.54	5,017	2,709	49,283	Mar 13 05:35 PM
Samsara BioCapital GP, LLC	10% Owner	Feb 12 '24	Buy	13.50	555,555	7,499,992	5,074,916	Feb 14 09:06 PM
Rodman David Malcom	Chief Medical Officer	Feb 12 '24	Option Exercise	0.84	11,366	9,566	44,266	Feb 13 04:08 PM
Rodman David Malcom	Chief Medical Officer	Jan 12 '24	Option Exercise	1.08	6,348	6,856	32,900	Jan 12 04:01 PM
Rodman David Malcom	Chief Medical Officer	Jan 11 '24	Option Exercise	0.54	5,017	2,709	26,552	Jan 12 04:01 PM
Rodman David Malcom	Chief Medical Officer	Dec 11 '23	Option Exercise	0.54	5,018	2,710	20,069	Dec 12 05:08 PM
Congleton Jon	Chief Executive Officer	Nov 22 '23	Buy	5.97	4,250	25,356	1,049,068	Nov 27 04:01 PM
Rodman David Malcom	Chief Medical Officer	Nov 13 '23	Option Exercise	0.54	5,017	2,709	15,051	Nov 14 06:18 PM
Rodman David Malcom	Chief Medical Officer	Nov 03 '23	Option Exercise	0.54	10,034	5,418	10,034	Nov 07 05:15 PM

SRRK

Scholar Rock Holding Corp

ALMS

Alumis Inc.

SYRS

Syros Pharmaceuticals Inc.

MLYS

Mineralys Therapeutics Inc

Upgrade your FINVIZ experience